Seminars in Radiation Oncology
Volume 18, Issue 2 , Pages 89-97 , April 2008

Tissue Microarrays in Clinical Oncology

  • David Voduc, MD, FRCPC

      Affiliations

    • Department of Radiation Oncology, British Columbia Cancer Agency, Vancouver, British Columbia, Canada.
    • Corresponding Author InformationAddress reprint requests to David Voduc, MD, FRCPC, Department of Radiation Oncology, BC Cancer Agency, 600 West 10th Ave, Vancouver, BC, Canada V5Z 4E6.
    • ,
  • Challayne Kenney, BMLSc

      Affiliations

    • Genetic Pathology Evaluation Centre, Vancouver, British Columbia, Canada.
    • ,
  • Torsten O. Nielsen, MD, PhD, FRCPC

      Affiliations

    • Department of Pathology, University of British Columbia, Vancouver, British Columbia, Canada.

References 

  1. Kononen J, Bubendorf L, Kallioniemi A. Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nat Med. 1998;4:844–847
  2. Liu CL, Montgomery KD, Natkunam Y. TMA-Combiner, a simple software tool to permit analysis of replicate cores on tissue microarrays. Mod Pathol. 2005;18:1641–1648
  3. Hughes-Davies L, Huntsman D, Ruas M. EMSY links the BRCA2 pathway to sporadic breast and ovarian cancer. Cell. 2003;115:523–535
  4. Moyano JV, Evans JR, Chen F. AlphaB-crystallin is a novel oncoprotein that predicts poor clinical outcome in breast cancer. J Clin Invest. 2006;116:261–270
  5. Tomlins SA, Rhodes DR, Perner S. Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science. 2005;310:644–648
  6. Eerola H, Heikkila P, Tamminen A. Histopathological features of breast tumours in BRCA1 (BRCA2 and mutation-negative breast cancer families). Breast Cancer Res. 2005;7:R93–R100
  7. Palacios J, Honrado E, Osorio A. Phenotypic characterization of BRCA1 and BRCA2 tumors based in a tissue microarray study with 37 immunohistochemical markers. Breast Cancer Res Treat. 2005;90:5–14
  8. Fan SQ, Ma J, Zhou J. Differential expression of Epstein-Barr virus-encoded RNA and several tumor-related genes in various types of nasopharyngeal epithelial lesions and nasopharyngeal carcinoma using tissue microarray analysis. Hum Pathol. 2006;37:593–605
  9. Alonso SR, Ortiz P, Pollan M. Progression in cutaneous malignant melanoma is associated with distinct expression profiles: a tissue microarray-based study. Am J Pathol. 2004;164:193–203
  10. Boddy JL, Fox SB, Han C. The androgen receptor is significantly associated with vascular endothelial growth factor and hypoxia sensing via hypoxia-inducible factors HIF-1a (HIF-2a, and the prolyl hydroxylases in human prostate cancer). Clin Cancer Res. 2005;11:7658–7663
  11. Hawk ET, Levin B. Colorectal cancer prevention. J Clin Oncol. 2005;23:378–391
  12. Kerlikowske K, Grady D, Rubin SM. Efficacy of screening mammography (A meta-analysis). JAMA. 1995;273:149–154
  13. Hammoud ZT, Badve S, Saxena R. A novel biomarker for the detection of esophageal adenocarcinoma. J Thorac Cardiovasc Surg. 2007;133:82–87
  14. Stewart JM, Fleshner N, Cole H. Comparison of annexin II, p63 and AMACR immunoreactivity in prostatic tissue: A tissue microarray study. J Clin Pathol. 2007;60:773–780
  15. Mhawech-Fauceglia P, Herrmann F, Bshara W. FLI-1 Expression in 4323 malignant and benign tumours: A multiple tumour tissue microarray analysis using polyclonal antibody. J Clin Pathol. 2007;60:694–700
  16. Kambham N, Kong C, Longacre TA. Utility of syndecan-1 (CD138) expression in the diagnosis of undifferentiated malignant neoplasms: A tissue microarray study of 1,754 cases. Appl Immunohistochem Mol Morphol. 2005;13:304–310
  17. Owens SR, Greenson JK. Immunohistochemical staining for p63 is useful in the diagnosis of anal squamous cell carcinomas. Am J Surg Pathol. 2007;31:285–290
  18. Au NH, Gown AM, Cheang M. P63 expression in lung carcinoma: A tissue microarray study of 408 cases. Appl Immunohistochem Mol Morphol. 2004;12:240–247
  19. Hans CP, Weisenburger DD, Greiner TC. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood. 2004;103:275–282
  20. Terry J, Saito T, Subramanian S. TLE1 as a diagnostic immunohistochemical marker for synovial sarcoma emerging from gene expression profiling studies. Am J Surg Pathol. 2007;31:240–246
  21. Stephenson AJ, Kattan MW. Nomograms for prostate cancer. BJU Int. 2006;98:39–46
  22. Ravdin PM, Siminoff LA, Davis GJ. Computer program to assist in making decisions about adjuvant therapy for women with early breast cancer. J Clin Oncol. 2001;19:980–991
  23. van de Rijn M, Gilks CB. Applications of microarrays to histopathology. Histopathology. 2004;44:97–108
  24. Ransohoff DF. Rules of evidence for cancer molecular-marker discovery and validation. Nat Rev Cancer. 2004;4:309–314
  25. Banham AH, Connors JM, Brown PJ. Expression of the FOXP1 transcription factor is strongly associated with inferior survival in patients with diffuse large B-cell lymphoma. Clin Cancer Res. 2005;11:1065–1072
  26. Sorlie T, Tibshirani R, Parker J. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci U S A. 2003;100:8418–8423
  27. Perou CM, Sorlie T, Eisen MB. Molecular portraits of human breast tumours. Nature. 2000;406:747–752
  28. Nielsen TO, Hsu FD, Jensen K. Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin Cancer Res. 2004;10:5367–5374
  29. Psyrri A, Yu Z, Weinberger PM. Quantitative determination of nuclear and cytoplasmic epidermal growth factor receptor expression in oropharyngeal squamous cell cancer by using automated quantitative analysis. Clin Cancer Res. 2005;11:5856–5862
  30. Yu Z, Weinberger PM, Haffty BG. Cyclin d1 is a valuable prognostic marker in oropharyngeal squamous cell carcinoma. Clin Cancer Res. 2005;11:1160–1166
  31. Deeb G, Wang J, Ramnath N. Altered E-cadherin and epidermal growth factor receptor expressions are associated with patient survival in lung cancer: A study utilizing high-density tissue microarray and immunohistochemistry. Mod Pathol. 2004;17:430–439
  32. Tan D, Li Q, Deeb G. Thyroid transcription factor-1 expression prevalence and its clinical implications in non-small cell lung cancer: A high-throughput tissue microarray and immunohistochemistry study. Hum Pathol. 2003;34:597–604
  33. Parikh RR, Yang Q, Haffty BG. Prognostic significance of vascular endothelial growth factor protein levels in T1-2 N0 laryngeal cancer treated with primary radiation therapy. Cancer. 2007;109:566–573
  34. Cho EI, Kowalski DP, Sasaki CT. Tissue microarray analysis reveals prognostic significance of COX-2 expression for local relapse in T1-2N0 larynx cancer treated with primary radiation therapy. Laryngoscope. 2004;114:2001–2008
  35. Paik S, Tang G, Shak S. Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. J Clin Oncol. 2006;24:3726–3734
  36. Paik S, Shak S, Tang G. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med. 2004;351:2817–2826
  37. Howell A, Cuzick J, Baum M. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years’ adjuvant treatment for breast cancer. Lancet. 2005;365:60–62
  38. Dowsett M. Biomarker investigations from the ATAC trial: The role of TA01. Breast Cancer Res Treat. 2004;87(suppl 1):S11–S18
  39. Dowsett M, Allred DC. Relationship between quantitative ER and PgR and Her2 status with recurrence in the ATAC trial. 2006;Presented at the 29th Annual San Antonio Breast Cancer Symposium. San Antonio, TX, December 14-17
  40. Keyomarsi K, Tucker SL, Buchholz TA. Cyclin E and survival in patients with breast cancer. N Engl J Med. 2002;347:1566–1575
  41. Porter PL, Barlow WE, Yeh IT. p27(Kip1) and cyclin E expression and breast cancer survival after treatment with adjuvant chemotherapy. J Natl Cancer Inst. 2006;98:1723–1731
  42. Wang L, Shao ZM. Cyclin e expression and prognosis in breast cancer patients: A meta-analysis of published studies. Cancer Invest. 2006;24:581–587
  43. Bubendorf L, Nocito A, Moch H. Tissue microarray (TMA) technology: Miniaturized pathology archives for high-throughput in situ studies. J Pathol. 2001;195:72–79
  44. Fitzgibbons PL, Murphy DA, Dorfman DM. Interlaboratory comparison of immunohistochemical testing for HER2: Results of the 2004 and 2005 College of American Pathologists HER2 Immunohistochemistry Tissue Microarray Survey. Arch Pathol Lab Med. 2006;130:1440–1445
  45. Dorfman DM, Bui MM, Tubbs RR. The CD117 immunohistochemistry tissue microarray survey for quality assurance and interlaboratory comparison: A College of American Pathologists Cell Markers Committee Study. Arch Pathol Lab Med. 2006;130:779–782
  46. de Jong D, Rosenwald A, Chhanabhai M. Immunohistochemical prognostic markers in diffuse large B-cell lymphoma: Validation of tissue microarray as a prerequisite for broad clinical applications—A study from the Lunenburg Lymphoma Biomarker Consortium. J Clin Oncol. 2007;25:805–812
  47. Cheang MC, Treaba DO, Speers CH. Immunohistochemical detection using the new rabbit monoclonal antibody SP1 of estrogen receptor in breast cancer is superior to mouse monoclonal antibody 1D5 in predicting survival. J Clin Oncol. 2006;24:5637–5644
  48. Selvarajan S, Tan SY, Sii LH. c-erbB-2 (HER-2/neu) immunohistochemistry in invasive breast cancer: Is there concordance between standard sections and tissue microarrays?. Pathology. 2006;38:316–320
  49. O’Grady A, Flahavan CM, Kay EW. HER-2 analysis in tissue microarrays of archival human breast cancer: Comparison of immunohistochemistry and fluorescence in situ hybridization. Appl Immunohistochem Mol Morphol. 2001;11:177–182
  50. Sapino A, Marchio C, Senetta R. Routine assessment of prognostic factors in breast cancer using a multicore tissue microarray procedure. Virchows Arch. 2006;449:288–296
  51. Horvath L, Henshall S. The application of tissue microarrays to cancer research. Pathology. 2001;33:125–129
  52. Simon R, Sauter G. Tissue microarrays for miniaturized high-throughput molecular profiling of tumors. Exp Hematol. 2002;30:1365–1372
  53. Torhorst J, Bucher C, Kononen J. Tissue microarrays for rapid linking of molecular changes to clinical endpoints. Am J Pathol. 2001;159:2249–2256
  54. Leversha MA, Fielding P, Watson S. Expression of p53, pRB, and p16 in lung tumours: A validation study on tissue microarrays. J Pathol. 2003;200:610–619
  55. Jourdan F, Sebbagh N, Comperat E. Tissue microarray technology: Validation in colorectal carcinoma and analysis of p53, hMLH1, and hMSH2 immunohistochemical expression. Virchows Arch. 2003;443:115–121
  56. Hoos A, Cordon-Cardo C. Tissue microarray profiling of cancer specimens and cell lines: Opportunities and limitations. Lab Invest. 2001;81:1331–1338
  57. Mirlacher M, Kasper M, Storz M. Influence of slide aging on results of translational research studies using immunohistochemistry. Mod Pathol. 2004;17:1414–1420

 David Voduc and Torsten O. Nielsen are supported by the National Institutes of Health Strategic Partnering to Evaluate Cancer Signatures program. Torsten O. Nielsen is a scholar of the Michael Smith Foundation for Health Research. The Genetic Pathology Evaluation Centre is supported by an unrestricted educational grant from sanofi-aventis.

PII: S1053-4296(07)00097-5

doi: 10.1016/j.semradonc.2007.10.006

Seminars in Radiation Oncology
Volume 18, Issue 2 , Pages 89-97 , April 2008

Article Tools

* Image Usage & Resolution